| Zacks Company Profile for Trinity Biotech PLC (TRIB : NSDQ) |
|
|
| |
| • Company Description |
| Trinity Biotech plc, headquartered in Bray, the Republic of Ireland, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market worldwide. The company provides two haemostasis product lines, Biopool and Amax, comprising test kits and instrumentation used for the detection of blood disorders. These products are used to detect autoimmune, infectious and sexually transmitted diseases, diabetes and disorders of the blood, liver and intestine. The Company is also a provider of raw materials to the life sciences industry. It also engages in the provision of engineering, financial, and management services, as well as in trading business. Trinity Biotech sells its products through its sales force, as well as through a network of distributors and strategic partners.
Number of Employees: 401 |
|
|
| |
| • Price / Volume Information |
| Yesterday's Closing Price: $0.75 |
Daily Weekly Monthly
 |
| 20 Day Moving Average: 2,404,859 shares |
| Shares Outstanding: 18.05 (millions) |
| Market Capitalization: $13.54 (millions) |
| Beta: 0.80 |
| 52 Week High: $3.44 |
| 52 Week Low: $0.48 |
| Short Interest Ratio: |
| |
% Price Change |
% Price Change Relative to S&P 500 |
| 4 Week |
17.92% |
11.54% |
| 12 Week |
33.93% |
12.36% |
| Year To Date |
-14.79% |
-20.19% |
|
|
|
|
| |
|
|
| |
| • General Corporate Information |
Officers
John Gillard - Chief Executive Officer
Louise Tallon - Interim Chief Financial Officer
Gary Keating - Chief Technology Officer
Tom Lindsay - Independent Director
Andrew Omidvar - Independent Director
|
|
Peer Information
Trinity Biotech PLC (BJCT)
Trinity Biotech PLC (CADMQ)
Trinity Biotech PLC (APNO)
Trinity Biotech PLC (UPDC)
Trinity Biotech PLC (IMTIQ)
Trinity Biotech PLC (CYGN)
|
|
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED PRODUCTS
Sector: Medical
CUSIP: 896438504
SIC: 2835
|
|
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 12/01/24
Next Expected EPS Date: 08/13/25
|
|
Share - Related Items
Shares Outstanding: 18.05
Most Recent Split Date: 2.00 (0.20:1)
Beta: 0.80
Market Capitalization: $13.54 (millions)
|
|
|
|
|
| |
| • EPS Information |
• Dividend Information |
| Analyst Coverage: No |
Dividend Yield: 0.00% |
| Current Fiscal Quarter EPS Consensus Estimate: $-0.37 |
Indicated Annual Dividend: $0.00 |
| Current Fiscal Year EPS Consensus Estimate: $-1.77 |
Payout Ratio: |
| Number of Estimates in the Fiscal Year Consensus: 1.00 |
Change In Payout Ratio: |
| Estmated Long-Term EPS Growth Rate: 20.00% |
Last Dividend Paid: NA - $0.00 |
| Next EPS Report Date: 08/13/25 |
|
|
|
| |
